
Malow also emphasized the importance of staying educated on the potential neurological risks that may occur as a result of climate change.

Malow also emphasized the importance of staying educated on the potential neurological risks that may occur as a result of climate change.

A significant portion of unvaccinated individuals were open to future vaccination.

The poll also showed that social media and general media coverage influenced about 33% of participants to not get vaccinated.

BIIB080 is designed to target microtubule-associated protein tau mRNA, aimed to reduce the production of tau protein.

Among the 9 surface disinfectants studied, only 2 demonstrated a reduction in viral titer below the limit of detection.

Notably, high levels of high-density lipoprotein cholesterol (HDL-C) were not associated with the risk of dementia following adjustments for triglyceride levels.

Pharmacists can address micronutrient deficiencies, aiding those with type 2 diabetes as they face a higher risk.

Tocilizumab-bavi received FDA approval in September 2023 as the first biosimilar to tocilizumab for the treatment of various adult and pediatric arthritis conditions.

No manufacturing or safety issues were identified, but the FDA stated the new drug application did not demonstrate efficacy in adequate and well-controlled studies.

Generics play a crucial role in mitigating drug shortages by offering a real alternative for 80% of drugs that are becoming increasingly unavailable in Italy.

Pharmacists play a crucial role in educating patients on proper administration and adherence to GLP-1 treatments.

These new phase 3 results indicate the effectiveness of the 2-dose 13-valent pneumococcal conjugate vaccine (PCV13) and 1-dose PCV20 regimens.

The only major change is in the included strain of influenza A/H2N2 virus, which has been updated for both the egg-based and the cell- and recombinant-based vaccines.

The Auto-Pure 2400 system combines liquid handling and magnetic cell isolation for efficient latent tuberculosis testing.

Reducing stigma, improving mental health benefits, and addressing workload concerns all need to happen simultaneously.

Current recommended levels of vitamin B12 might not be sufficient to protect against neurological decline.

John Ostrominski, MD shares insights into the safety and efficacy of finerenone, based on data from the FINEARTS-HF trial.

The CDC reports 483 total cases across 20 states as of March 28, 2025.

M3P will be a financial lifeline for seniors while lowering certain pharmacy costs, but more education and tools are needed to make it successful with pharmacies and their customers.

The Protecting Pharmacies in Medicaid Act aims to tackle spread pricing, but other legislation could target different issues.

Expert shares insights on leadership resilience, emphasizing self-awareness, team development, and maintaining personal worth beyond professional achievements.

Pharmacists play a key role in COVID-19 management by educating patients on treatment, monitoring drug interactions, promoting vaccination, and addressing hesitancy.

A phase 1/2 clinical trial will provide crucial data on the vaccine's tolerability and pave the way for future development and potential widespread use.

The risk of developing HZ in this population is 10 to 30 times higher than in the general population.

Experts discuss Project Lifeline’s integration of SBIRT in community pharmacies, highlighting its effectiveness in identifying and addressing opioid use disorder while exploring strategies for broader implementation.

Marc Humbert, MD, PhD, shared data that were presented at the ACC 2025 Scientific Sessions.

John Buse, MD, PhD discusses the expanding role of GLP-1 receptor agonists in treatment of cardiovascular conditions.

The trial is the first to test the cardiovascular benefits of an oral glucagon-like peptide-1 (GLP-1) agonist.

Christian Ruff, MD, highlights abelacimab’s potential to significantly reduce bleeding in patients with high-risk atrial fibrillation.

The STRIDE trial was first of its kind to evaluate the use of a GLP-1 agonist in PAD management.